Tandem Meetings

Omidubicel May Provide Long-Term Benefits With Allogeneic Transplantation for Hematologic Malignancies

Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.

Adding Eprenetapopt to Maintenance Azacitidine Promising After HCT in MDS/AML

Researchers sought to determine whether adding eprenetapopt to maintenance azacitidine after HCT would be effective in patients with AML or MDS.

Disparity in Access to CAR-T Therapy Associated With Lower Income Neighborhoods

Researchers sought to determine the reasons for a disparity in patients who receive CAR-T therapy.

Relapse Risk Lower With Double CBT Than With Matched Sibling or Unrelated Transplant

There was no significant difference in transplant-related mortality or overall survival.

Transplant Approach Produces “Promising” Long-Term Outcomes in Kids With Blood Cancers

The approach resulted in low rates of graft failure, viral infections, and relapse.

Costs of Care and Complication Rates Among Patients With Hematologic Malignancies Undergoing Allo-HCT

Researchers sought to determine the costs of care and health resource use of patients with hematologic malignancies undergoing allo-HCT.

Outcomes of Pediatric Patients With Steroid-Refractory Acute Graft Vs Host Disease

Steroid-refractory acute GVHD is associated with high mortality rates in pediatric patients, despite second-line treatment.

Lenalidomide Maintenance Superior to Bortezomib for Myeloma Patients With Abn1q

Among patients with Abn1q, those who received bortezomib-based maintenance had significantly worse progression-free survival and overall survival.

Results Support Allo-HSCT After CAR-T Failure in Large B-Cell Lymphoma

The 1-year progression-free survival rate was 45%, and the 1-year overall survival rate was 59%.

Real-World Data Confirm Lack of Standard Care for Triple-Exposed Multiple Myeloma

After triple-class exposure, patients received more than 50 unique treatment regimens.